Revenio Group OyjREVXF 82 PB Ratio is 3.22 as of Jul. 05, 2026, which is 75% below its 10-year median of 13.14. GuruFocus rates REVXF with a GF Score™ of 82/100 and a GF Value™ of $40.45 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 61.04% on this metric.
Revenio Group Oyj stock PB Ratio (=2.84) is close to 10-year low of 2.82.
The historical rank and industry rank for Revenio Group Oyj's PB Ratio or its related term are showing as below:
REVXF'
s PB Ratio Range Over the Past 10 Years
Min: 2.82 Med: 13.14 Max: 42.3
Current: 2.84
During the past 13 years, Revenio Group Oyj's highest PB Ratio was 42.30. The lowest was 2.82. And the median was 13.14.
REVXF's PB Ratio is ranked worse than 61.04% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs REVXF: 2.84
During the past 12 months, Revenio Group Oyj's average Book Value Per Share Growth Rate was 4.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 25.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Revenio Group Oyj was 69.80% per year. The lowest was -15.60% per year. And the median was 8.45% per year.
Back to Basics: PB Ratio
Revenio Group Oyj (OTCPK:REVXF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Revenio Group Oyj PB Ratio Related Terms
Revenio Group Oyj PB Ratio Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's PB Ratio distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Revenio Group Oyj (REVXF) has a PB Ratio of 3.22 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Revenio Group Oyj and its competitors. This is 75% below median its historical median of 13.14. Over the past decade, Revenio Group Oyj's PB Ratio has ranged from 2.82 to 42.30. According to the industry distribution chart, Revenio Group Oyj ranks #481 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 61%.
Is Revenio Group Oyj's PB Ratio too high?
Revenio Group Oyj's current PB Ratio of 3.22 is 75% below median its 10-year median of 13.14. Over the past 10 years, this metric has ranged from a low of 2.82 to a high of 42.30. The Medical Devices & Instruments industry median PB Ratio is 2.07. Revenio Group Oyj's value of 3.22 is 55.6% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #481 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #481 out of 788 companies for PB Ratio. This places Revenio Group Oyj in the lower half of its industry. The industry median PB Ratio is 2.07. Revenio Group Oyj's value of 3.22 is 55.6% above this benchmark. Historically, Revenio Group Oyj's own PB Ratio has ranged from 2.82 to 42.30 over the past decade. While the company's 10-year median is 13.14 vs. the industry median of 2.07, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current PB Ratio of 3.22 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current PB Ratio is 3.22, which is 75% below median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.45, compared to a current price of $16.41 — trading 59.4% below its estimated fair value. The current PB Ratio is 3.22, which is 75% below median its 10-year median of 13.14 and 55.6% above the Medical Devices & Instruments industry median of 2.07. Revenio Group Oyj's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current PB Ratio is 3.22 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 59.4% below its estimated GF Value™ of $40.45.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
PB Ratio: 3.22 (75% below median its 10-year median of 13.14)
GF Value™: $40.45 vs. price of $16.41 (59.4% below fair value)
Industry Position: 55.6% above the Medical Devices & Instruments median (#481 of 788)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score
Get the complete analysis for REVXF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
